Innoviva, Inc. - Common Stock (INVA)
Frequently Asked Questions About Innoviva, Inc. - Common Stock (INVA)
Does Innoviva, Inc. focus solely on respiratory diseases?
While Innoviva, Inc. has made significant strides in the development of therapies for respiratory diseases, the company's mission extends beyond that to include other therapeutic areas. It continuously seeks opportunities to develop innovative treatments across various medical fields.
How can investors learn more about Innoviva, Inc.?
Investors can learn more about Innoviva, Inc. by visiting the official company website, reviewing SEC filings, and examining investor relations materials. These resources provide insights into the company’s financial performance, product pipeline, and strategic initiatives.
How does Innoviva, Inc. address compliance and regulatory requirements?
Innoviva, Inc. prioritizes compliance with regulatory requirements set forth by health authorities such as the FDA. This includes adhering to Good Manufacturing Practices (GMP), maintaining transparency in clinical trials, and ensuring the safety and efficacy of its products for patients.
How does Innoviva, Inc. engage with the community?
Innoviva, Inc. actively engages with the community by participating in health fairs, educational initiatives, and partnerships with local healthcare organizations. The company is committed to raising awareness about respiratory diseases and promoting access to effective therapies.
How does Innoviva, Inc. prioritize research and development?
Research and development are central to Innoviva, Inc.’s operations. The company invests significantly in clinical trials and studies to ensure that its therapeutic candidates undergo rigorous testing and validation before reaching the market, thereby prioritizing patient safety and efficacy.
How has Innoviva, Inc. been impacted by market trends?
Innoviva, Inc. has been influenced by market trends such as the increasing demand for respiratory treatments and innovation in drug delivery technologies. The company adapts to these trends by aligning its research efforts and marketing strategies to meet the evolving needs of patients and healthcare providers.
Is Innoviva, Inc. involved in any partnerships?
Yes, Innoviva, Inc. engages in partnerships with other biopharmaceutical companies, notably with GlaxoSmithKline, to enhance its research capabilities and expedite the development of its product pipeline. These collaborations are essential for broadening its therapeutic offerings and reaching new markets.
What are some key products of Innoviva, Inc.?
Innoviva, Inc. is known for its partnership in developing innovative respiratory medications, including the inhalation product Trelegy Ellipta. This product is used to manage chronic obstructive pulmonary disease (COPD) and is a result of their collaboration with GlaxoSmithKline.
What are the future goals of Innoviva, Inc.?
Innoviva, Inc.'s future goals include expanding its product portfolio, enhancing research and development in innovative therapies, and building strategic partnerships that will drive growth. The company aims to be a leader in the biopharmaceutical industry by delivering effective treatments to patients.
What does Innoviva, Inc. do?
Innoviva, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat respiratory diseases, as well as other areas in need of better treatment options. The company partners with biopharmaceutical organizations to enhance and expedite the development of products that aim to improve patient outcomes.
What is the business model of Innoviva, Inc.?
Innoviva, Inc. employs a business model that emphasizes collaboration and partnership with other companies in the biopharmaceutical sector. Through licensing agreements and joint ventures, Innoviva aims to accelerate the development and commercialization of its product pipeline.
What is the significance of Trelegy Ellipta for Innoviva, Inc.?
Trelegy Ellipta is a flagship product for Innoviva, Inc., representing a significant revenue stream and showcasing the company’s capabilities in developing complex therapies. Its success is vital for establishing Innoviva as a key player in the respiratory treatment market.
What is the stock symbol for Innoviva, Inc.?
The stock symbol for Innoviva, Inc. is INVA, and it is traded on the NASDAQ stock exchange. Investors can buy and sell shares of Innoviva using this ticker symbol, allowing for participation in the company's growth.
What performance metrics is Innoviva, Inc. known for?
Innoviva, Inc. tracks various performance metrics, including revenue growth from its therapeutic products, the advancement of its research pipeline, and overall market share in the therapeutic areas it targets. These metrics are critical in assessing the company’s success and strategic direction.
What recent developments or news has Innoviva, Inc. announced?
Innoviva, Inc. frequently announces developments related to its product pipeline and partnerships. Recent news may include updates on clinical trial results, new collaborations, or regulatory approvals that significantly impact the company’s portfolio and market position.
What therapeutic areas is Innoviva, Inc. exploring?
While Innoviva, Inc. has a robust focus on respiratory diseases, it is also exploring opportunities in other therapeutic areas where innovative treatments may significantly improve patient outcomes. This includes research initiatives aimed at addressing unmet medical needs.
When was Innoviva, Inc. founded?
Innoviva, Inc. was founded in 1996, originally under the name Theravance, Inc. It has since evolved its focus and rebranded to Innoviva, reflecting the company's dedication to innovative therapies in the biopharmaceutical sector.
Where is Innoviva, Inc. headquartered?
Innoviva, Inc. is headquartered in South San Francisco, California. This strategic location enables the company to stay at the forefront of the vibrant biotechnology sector in the San Francisco Bay Area.
Who are the key executives at Innoviva, Inc.?
Innoviva, Inc. is led by a team of experienced executives, with the CEO providing strategic direction for the company. The leadership team has expertise in drug development, commercialization, and corporate operations, which positions Innoviva for continued growth and success.
What is the current price of Innoviva, Inc. - Common Stock?
The current price of Innoviva, Inc. - Common Stock is 21.62
When was Innoviva, Inc. - Common Stock last traded?
The last trade of Innoviva, Inc. - Common Stock was at 2:18 pm EDT on June 12th, 2025
What is the market capitalization of Innoviva, Inc. - Common Stock?
The market capitalization of Innoviva, Inc. - Common Stock is 1.42B
How many shares of Innoviva, Inc. - Common Stock are outstanding?
Innoviva, Inc. - Common Stock has 65.50M shares outstanding.